Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Pembrolizumab/Lenvatinib Approaches EU Approval for Select RCC and Endometrial Carcinoma

October 15th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of the combination of pembrolizumab and lenvatinib for 2 indications: select patients with renal cell carcinoma and select patients with endometrial carcinoma.

Choueiri Shares Highlights From the 2021 Kidney Cancer Research Summit

October 14th 2021

Toni Choueiri, MD, discusses key highlights from the 2021 Kidney Cancer Research Summit and exciting research efforts underway in renal cell carcinoma.

Dr. Msaouel on Reducing Risk Factors for Renal Medullary Carcinoma With Exercise

October 11th 2021

Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.

Dr. Jonasch on Pivotal Developments in the Treatment of RCC

October 11th 2021

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

Maintenance Therapy, Adjuvant and Escalated Approaches Garner Excitement in GU Cancers

October 11th 2021

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.

Dr. Zhang on the Key Objectives of the PDIGREE Trial in Advanced RCC

October 8th 2021

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE trial, evaluating the combination ipilimumab plus nivolumab, followed by nivolumab with or without cabozantinib, in patients with advanced renal cell cancer.

Dr. Zarrabi on the Real-World Data With Axitinib/Pembrolizumab Vs Ipilimumab/Nivolumab in Clear Cell RCC

October 8th 2021

Kevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.

Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

October 6th 2021

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Makes an Impression in Advanced RCC

October 6th 2021

Robert J. Motzer, MD, spoke about the “exceptional” efficacy of the combination and how it fits into the evolving RCC treatment landscape.

Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer

September 30th 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Frontline Treatments for Metastatic RCC March Forward

September 30th 2021

Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.

Checkpoint Inhibitors Demonstrate Broad Reach in GU Cancers

September 28th 2021

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.

Enfortumab Vedotin Approved in Japan for Advanced Urothelial Cancer

September 27th 2021

The Japanese Ministry of Health, Labour, and Welfare has approved enfortumab vedotin for the treatment of patients with unresectable urothelial carcinoma that has progressed following chemotherapy.

VHL-Mutated and VHL Wild-Type Clear Cell RCC May Present Similar Clinical Characteristics

September 17th 2021

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

Improved Communication Needed for Patients With RCC Subtype

September 17th 2021

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

Frontline Immunotherapy Improves Survival in Advanced RCC, But Benefit to Be Determined for Favorable-Risk Subset

September 16th 2021

Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.

Pembrolizumab/Axitinib Combo Demonstrates Long-Term OS Benefit in Clear Cell RCC

September 16th 2021

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCC

September 13th 2021

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

NEJM Data Underscore DFS Benefit With Adjuvant Pembrolizumab in Post-Nephrectomy RCC

September 7th 2021

Adjuvant treatment with pembrolizumab led to a significant improvement in disease-free survival compared with placebo after nephrectomy in patients with renal cell carcinoma who are at high risk for recurrence, as underscored by data from the pivotal phase 3 KEYNOTE-564 trial.